Composition and methods for highly efficient gene transfer using AAV capsid variants

Patent metadata

Field	Value
Publication number	US-9909142-B2
Application number	US-201314394454-A
Country	US
Kind code	B2
Filing date	Apr 18, 2013
Priority date	Apr 18, 2012
Publication date	Mar 6, 2018
Grant date	Mar 6, 2018

Abstract

Compositions and methods for AAV mediated gene therapy are disclosed. AAV vectors comprise protein capsid variants comprising therapeutically beneficial transgenes. AAV variants are provided which exhibit increased transduction efficiency when compared to AAV serotypes (e.g., AAV1, AAV2, AAV8, AAV-rh74), which lack the modifications disclosed herein. Such improved vectors are useful for transduction of a variety of tissues.

First claim

What is claimed is:

1. An adeno-associated virus (AAV) vector comprising a VP1 capsid protein comprising one or more lysine substitutions at position 61, K61R, at position 84, K84R, at position 137, K137R, at position 143, K143R, at position 161, K161R, at position 459, K459R, at position 533, K533R, or at position 707, K707R of AAV1 VP1 capsid protein, said vector further comprising a minigene comprising AAV inverted terminal repeats and a heterologous nucleic acid sequence operably linked to regulatory sequences which direct expression of a product from the heterologous nucleic acid sequence in a host cell, said lysine substitution being effective to inhibit ubiquitination of said capsid protein, thereby increasing transduction of said AAV vector into a target cell, compared to an AAV vector comprising the AAV1 VP1 capsid protein without the one or more lysine substitutions.

2. An adeno-associated virus (AAV) vector comprising a VP1 capsid protein comprising one or more lysine substitutions at position 39, K39R, at position 137, K137R, at position 143, K143R, at position 161, K161R, at position 490, K490R, at position 527, K527R, or at position 532, K532R of AAV2 VP1 capsid protein, said vector further comprising a minigene comprising AAV inverted terminal repeats and a heterologous nucleic acid sequence operably linked to regulatory sequences which direct expression of a product from the heterologous nucleic acid sequence in a host cell, said lysine substitution being effective to inhibit ubiquitination of said capsid protein, thereby increasing transduction of said AAV vector into a target cell, compared to an AAV vector comprising the AAV2 VP1 capsid protein without the one or more lysine substitutions.

3. An adeno-associated virus (AAV) vector comprising a VP1 capsid protein comprising one or more lysine substitutions at position 137, K137R, at position 259, K259R, at position 333, K333R, at position 530, K530R, at position 569, K569R, or at position 668, K668R, of AAV8 VP1 capsid protein, said vector further comprising a minigene comprising AAV inverted terminal repeats and a heterologous nucleic acid sequence operably linked to regulatory sequences which direct expression of a product from the heterologous nucleic acid sequence in a host cell, said lysine substitution being effective to inhibit ubiquitination of said capsid protein, thereby increasing transduction of said AAV vector into a target cell, compared to an AAV vector comprising the AAV8 VP1 capsid protein without the one or more lysine substitutions.

4. An adeno-associated virus (AAV) vector comprising a VP1 capsid protein comprising one or more lysine substitutions at position 26, K26R, at position 38, K38R, at position 51, K51R, at position 61, K61R, at position 77, K77R, at position 137, K137R, at position 169, K169R, at position 259, K259R, at position 333, K333R, at position 530, K530R, at position 547, K547R, at position 552, K552R, at position 569, K569R or at position 709, K709R of AAV-rh74 VP1 capsid protein, said vector further comprising a minigene comprising AAV inverted terminal repeats and a heterologous nucleic acid sequence operably linked to regulatory sequences which direct expression of a product from the heterologous nucleic acid sequence in a host cell, said lysine substitution being effective to inhibit ubiquitination of said capsid protein, thereby increasing transduction of said AAV vector into a target cell, compared to an AAV vector comprising the AAV-rh74 VP1 capsid protein without the one or more lysine substitutions.

5. The AAV vector according to any one of claims 1 - 4 , wherein the expression product of the heterologous nucleic acid sequence is a therapeutic peptide or nucleic acid.

6. The AAV vector according to claim 5 , wherein the therapeutic peptide is a coagulation factor selected from the group consisting of Factor VIII, Factor IX or a functional fragment thereof.

7. The AAV vector according to any one of claims 1 - 4 , wherein the expression product of the heterologous nucleic acid sequence is an IgG, IgM, IgA, IgD, IgE, chimeric immunoglobulin, humanized antibody, or a single chain antibody.

8. The AAV vector according to claim 7 , wherein the expression product of the heterologous nucleic acid sequence is a chimeric immunoglobulin.

9. The AAV vector according to any one of claims 1 - 4 , wherein the expression product of the heterologous nucleic acid sequence is a single chain antibody.

10. The AAV vector according to any one of claims 1 - 4 , wherein the expression product is an antiviral RNAi.

11. The AAV vector of claim 10 , wherein said inhibitory RNA is effective to inhibit HCV infection and replication.

12. The AAV vector of claim 10 , wherein said inhibitory RNA is effective to inhibit expression of a eukaryotic target gene.

13. The AAV vector according to any one of claims 1 - 4 , wherein the expression product of the heterologous nucleic acid sequence is a disease-modifying cytokine.

14. The AAV vector according to any one of claims 1 - 4 , wherein the expression product of the heterologous nucleic acid sequence is a pair of zinc finger nucleases.

15. The AAV vector according to any one of claims 1 - 4 comprising 2, 3, or 4 lysine substitutions.

16. The AAV vector according to any one of claims 1 - 4 , wherein the expression product is Factor VIII.

17. The AAV vector according to any one of claims 1 - 4 , wherein the expression product is Factor IX.

18. A pharmaceutical composition comprising the AAV vector according to any one of claims 1 - 4 , and a physiological compatible carrier therefor.

19. A cell culture comprising the AAV vector according to any one of claims 1 - 4 .

Assignees

• Childrens Hospital Philadelphia

Inventors

• Yazicioglu Mustafa N
• Mingozzi Federico
• Anguela Xavier
• High Katherine A

Classifications

• A61P7/04

  Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents · CPC title

• A61P31/14

  for RNA viruses · CPC title

• A61K48/00 Primary

  Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy · CPC title

• C12N2750/14122

  New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes · CPC title

• C12N2750/14143

  viral genome or elements thereof as genetic vector · CPC title